Lin J
Institute of Liver Diseases, Tongji Hospital, Tongji Medical University, Wuhan.
Zhonghua Yi Xue Za Zhi. 1992 Feb;72(2):86-7, 128.
By means of immunohistochemical technique ABC, using monoclonal anti-transferrin receptor (TFR) antibodies WuT9 and OKT9, TFR expression in 30 cases of hepatocellular carcinoma (HCC) and in 6 cases of organs and tissues of normal human bodies was studied. It was revealed that large amount of TFR were expressed in liver cancer cells, but not in the surrounding mesenchymal cells as demonstrated by intense immunostaining in cancer nests, and even not in the surrounding mesenchyma of those HCC patients with negative AFP in their serum. In normal human body, only small amount of TFR in limited sites was found without free antigen in blood stream. Thus, it followed that TFR as a structural antigen of HCC was expressed with higher relative specificity than AFP, and TFR may be considered a tumor marker and therapeutic target of HCC.
采用免疫组织化学ABC技术，使用抗转铁蛋白受体（TFR）单克隆抗体WuT9和OKT9，研究了30例肝细胞癌（HCC）及6例正常人体器官和组织中TFR的表达情况。结果显示，肝癌细胞中大量表达TFR，但癌巢中强烈免疫染色表明周围间充质细胞不表达，血清AFP阴性的HCC患者周围间充质中也不表达。在正常人体中，仅在有限部位发现少量TFR，血流中无游离抗原。因此，TFR作为HCC的一种结构抗原，其表达具有比AFP更高的相对特异性，TFR可被视为HCC的肿瘤标志物和治疗靶点。
